SELLAS Life Sciences Group Inc (SLS):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:SELLAS Life Sciences Group Inc (SLS) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7501
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
SELLAS Life Sciences Group Inc (SELLAS), formerly Galena Biopharma Inc, is a clinical-stage biopharmaceutical company that develops novel cancer immunotherapeutics for a broad range of cancer indications. Its lead product candidate, galinpepimut-S, is a Wilms Tumor 1 (WT1) protein-targeting synthetic heteroclitic epitope immunotherapeutic antigen used for the treatment of acute myeloid leukemia (AML), ovarian cancer, malignant pleural mesothelioma (MPM), multiple myeloma, and solid tumors. Its pipeline includes NeuVax (nelipepimut-S), a vaccine derived from the human epidermal growth factor 2 or HER2 – protein to treat breast cancer; GALE-301 and GALE-302, vaccines derived from the folate binding protein (FBP) to treat ovarian cancer; and GALE-401, a controlled release anagrelide for thrombocythemia. SELLAS is headquartered in New York City, New York, the US.

SELLAS Life Sciences Group Inc (SLS) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
SELLAS Life Sciences Group Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
SELLAS Life Sciences Group Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
SELLAS Life Sciences Group Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
SELLAS Life Sciences Group Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
SELLAS Life Sciences Group Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
SELLAS Life Sciences Group Inc, Medical Equipment, Deal Details 11
Partnerships 11
Sellas Life Sciences Enters into Research Agreement with National Institutes of Health 11
Galena Biopharma Enters Into Co-Development Agreement With Leica Biosystems 12
Equity Offering 13
SELLAS Life Sciences Raises USD24.2 Million in Public Offering of Shares 13
SELLAS Life Sciences Plans to Raise USD18 Million in Public Offering of Shares 15
SELLAS Life Sciences Raises USD4.6 Million in Second Tranche of Private Placement of Preferred Stock and Warrants 16
SELLAS Life Sciences Raises USD6 Million in First Tranche of Private Placement of Preferred Stock and Warrants 17
Galena Biopharma Raises Up to USD15.5 Million in Public Offering of Shares and Warrants 18
Galena Biopharma to Raise Funds in Public Offering of Shares 20
Galena Biopharma Raises USD12.6 Million in Private Placement of Shares and Warrants 21
Galena Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares and Warrants for USD43 Million 23
SELLAS Life Sciences Group Inc – Key Competitors 25
SELLAS Life Sciences Group Inc – Key Employees 26
SELLAS Life Sciences Group Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Apr 16, 2018: SELLAS Life Sciences Reports Corporate Highlights, Advancements for its Cancer Immunotherapy Pipeline and 2017 Financial Results 28
Nov 09, 2017: Galena Biopharma Reports Third Quarter 2017 Financial Results 30
Aug 14, 2017: Galena Biopharma Reports Second Quarter 2017 Financial Results 32
May 10, 2017: Galena Biopharma Reports First Quarter 2017 Financial Results 35
Mar 15, 2017: Galena Biopharma Reports Fourth Quarter and Year End 2016 Financial Results and Provides a Corporate Update 38
Corporate Communications 42
Apr 20, 2018: SELLAS Life Sciences Announces Appointment Of Gene Mack As Chief Financial Officer And Treasurer 42
Mar 21, 2018: SELLAS Life Sciences Announces Appointment of Barbara A. Wood as Executive Vice President, General Counsel and Corporate Secretary 43
Feb 01, 2018: Women In Bio Announces Jane Wasman Appointed Chair of Sellas Life Sciences’ Board of Directors 44
Feb 21, 2017: Galena Biopharma Board of Directors Appoints Stephen F. Ghiglieri as Interim Chief Executive Officer 45
Jan 31, 2017: Galena Biopharma Announces the Resignation of its President and Chief Executive Officer and the Evaluation of Strategic Alternatives 46
Other Significant Developments 47
Jul 12, 2017: Galena Biopharma Provides Corporate Update 47
Jan 05, 2017: Galena Biopharma to Provide Corporate and Clinical Update and 2017 Outlook During Presentation at Biotech Showcase 2017 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
SELLAS Life Sciences Group Inc, Medical Equipment, Key Facts, 2017 2
SELLAS Life Sciences Group Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
SELLAS Life Sciences Group Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
SELLAS Life Sciences Group Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
SELLAS Life Sciences Group Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
SELLAS Life Sciences Group Inc, Deals By Market, 2012 to YTD 2018 9
SELLAS Life Sciences Group Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Sellas Life Sciences Enters into Research Agreement with National Institutes of Health 11
Galena Biopharma Enters Into Co-Development Agreement With Leica Biosystems 12
SELLAS Life Sciences Raises USD24.2 Million in Public Offering of Shares 13
SELLAS Life Sciences Plans to Raise USD18 Million in Public Offering of Shares 15
SELLAS Life Sciences Raises USD4.6 Million in Second Tranche of Private Placement of Preferred Stock and Warrants 16
SELLAS Life Sciences Raises USD6 Million in First Tranche of Private Placement of Preferred Stock and Warrants 17
Galena Biopharma Raises Up to USD15.5 Million in Public Offering of Shares and Warrants 18
Galena Biopharma to Raise Funds in Public Offering of Shares 20
Galena Biopharma Raises USD12.6 Million in Private Placement of Shares and Warrants 21
Galena Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares and Warrants for USD43 Million 23
SELLAS Life Sciences Group Inc, Key Competitors 25
SELLAS Life Sciences Group Inc, Key Employees 26
SELLAS Life Sciences Group Inc, Other Locations 27
SELLAS Life Sciences Group Inc, Subsidiaries 27

List of Figures
SELLAS Life Sciences Group Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
SELLAS Life Sciences Group Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
SELLAS Life Sciences Group Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
SELLAS Life Sciences Group Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
SELLAS Life Sciences Group Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
SELLAS Life Sciences Group Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
SELLAS Life Sciences Group Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
SELLAS Life Sciences Group Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[SELLAS Life Sciences Group Inc (SLS):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Achillion Pharmaceuticals Inc (ACHN):製薬・医療:M&Aディール及び事業提携情報
    Summary Achillion Pharmaceuticals Inc (Achillion) is a biopharmaceutical company which focuses on the discovery and development of small molecule therapeutic products for treatment of infectious diseases and immune system disorders. The company focuses at developing life-saving medicines to patients …
  • Allied Hotel Properties Inc:企業の戦略・SWOT・財務情報
    Allied Hotel Properties Inc - Strategy, SWOT and Corporate Finance Report Summary Allied Hotel Properties Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Link Healthcare Pty Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Link Healthcare Pty Ltd (LINK), a subsidiary of Clinigen Group Plc, is a healthcare solution provider that provides generic products. The company offers therapeutic products, prescription, OTC medicines and medical devices in various therapeutic areas. It offers products such as relistor, an …
  • CLP Holdings Ltd (00002):電力:M&Aディール及び事業提携情報
    Summary CLP Holdings Ltd (CLP) is an investor and operator in the energy sector of Asia Pacific region. The company invests in power generation, transmission and distribution, and electricity and gas retail activities. Its portfolio includes equity generating and purchase capacities. CLP’s generatio …
  • Arla Foods amba:企業のM&A・事業提携・投資動向
    Arla Foods amba - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Arla Foods amba Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Nagacorp Ltd:戦略・SWOT・企業財務分析
    Nagacorp Ltd - Strategy, SWOT and Corporate Finance Report Summary Nagacorp Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Sharps Compliance Corp (SMED):企業の財務・戦略的SWOT分析
    Summary Sharps Compliance Corp (Sharps) is a healthcare waste solution company that offers regulatory compliant services. The company offers products such as sharps disposal systems, public sharps safety, takeaway medication recovery system, collection and disposal system, complete needle collection …
  • Orkla ASA:企業のM&A・事業提携・投資動向
    Orkla ASA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Orkla ASA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Life Insurance Corporation of India:企業の戦略的SWOT分析
    Life Insurance Corporation of India - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Diamond Offshore Drilling, Inc.:企業の戦略・SWOT・財務情報
    Diamond Offshore Drilling, Inc. - Strategy, SWOT and Corporate Finance Report Summary Diamond Offshore Drilling, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Atlantic Power Corporation (ATP):電力:M&Aディール及び事業提携情報
    Summary Atlantic Power Corporation (Atlantic Power) is an electric utility that owns and operates diversified power generation assets. It produces electricity from various sources including biomass, coal, hydro, and natural gas sources. The company sells power to utilities and other large commercial …
  • Ascena Retail Group Inc (ASNA):企業の財務・戦略的SWOT分析
    Ascena Retail Group Inc (ASNA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Vienna Insurance Group AG:企業の戦略・SWOT・財務情報
    Vienna Insurance Group AG - Strategy, SWOT and Corporate Finance Report Summary Vienna Insurance Group AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Terumo BCT Inc-医療機器分野:企業M&A・提携分析
    Summary Terumo BCT Inc (Terumo BCT), a subsidiary of Terumo Corp, provides blood component, therapeutic apheresis, and cellular technologies. The company’s product portfolio include automated blood collection system, information system, data collection system, apheresis system, cell processor, cell …
  • Panalpina World Transport (Holding) Ltd (PWTN):企業の財務・戦略的SWOT分析
    Panalpina World Transport (Holding) Ltd (PWTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Monteloeder S.L.:企業の戦略・SWOT・財務情報
    Monteloeder S.L. - Strategy, SWOT and Corporate Finance Report Summary Monteloeder S.L. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • DRB-HICOM Defense Technologies Sdn Bhd:企業の戦略・SWOT・財務情報
    DRB-HICOM Defense Technologies Sdn Bhd - Strategy, SWOT and Corporate Finance Report Summary DRB-HICOM Defense Technologies Sdn Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Witte Molen NV:企業の戦略・SWOT・財務分析
    Witte Molen NV - Strategy, SWOT and Corporate Finance Report Summary Witte Molen NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Petroleum Development Oman LLC:企業の戦略的SWOT分析
    Petroleum Development Oman LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Leap Therapeutics Inc (LPTX)-医療機器分野:企業M&A・提携分析
    Summary Leap Therapeutics Inc (Leap Therapeutics) is a clinical-stage biopharmaceutical company that acquires, develops novel therapeutics for cancer research. The company’s pipeline encompasses DKN-01, a humanized monoclonal antibody that targets the Dickkopf-1 (DKK-1) protein, and in clinical tria …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆